National trends in pediatric systemic lupus erythematosus hospitalization in the United States: 2000-2009

Journal of Rheumatology

Volumn 41, Issue 3, 2014, Pages 539-546

  Knight, Andrea M ^a,b   Weiss, Pamela F ^a,b   Morales, Knashawn H ^a,c   Keren, Ron ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hospitalization; Length of stay; Mortality; Pediatric; Systemic lupus erythematosus

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; BLOOD VESSEL CATHETERIZATION; CAUSE OF DEATH; CHILD; CROSS-SECTIONAL STUDY; DIALYSIS; DISEASE ASSOCIATION; ETHNICITY; FEMALE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; ICD-9; LENGTH OF STAY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREND STUDY; UNITED STATES;

HOSPITALIZATION; LENGTH OF STAY; MORTALITY; PEDIATRIC; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; LENGTH OF STAY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84895480981     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130592     Document Type: Article

References (22)

1. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 2010;6:538-46.
2. Zhu TY, Tam LS, Li EK. Cost-of-illness studies in systemic lupus erythematosus: a systematic review. Arthritis Care Res 2011;63:751-60.
3. Slawsky KA, Fernandes AW, Fusfeld L, Manzi S, Goss TF. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. Arthritis Care Res 2011; 63:1224-32.
4. Krishnan E. Hospitalization and mortality of patients with systemic lupus erythematosus. J Rheumatol 2006;33:1770-4. (Pubitemid 44373209)
5. Brunner HI, Sherrard TM, Klein-Gitelman MS. Cost of treatment of childhood-onset systemic lupus erythematosus. Arthritis Rheum 2006;55:184-8.
6. Karve S, Candrilli S, Kappelman MD, Tolleson-Rinehart S, Tennis P, Andrews E. Healthcare utilization and comorbidity burden among children and young adults in the United States with systemic lupus erythematosus or inflammatory bowel disease. J Pediatr 2012;161:662-70.
7. Tanzer M, Tran C, Messer KL, Kroeker A, Herreshoff E, Wickman L, et al. Inpatient healthcare utilization by children and adolescents with systemic lupus erythematosus and kidney involvement. Arthritis Care Res 2013;65:382-90.
8. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
9. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28. (Pubitemid 41697285)
10. Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006;70:732-42. (Pubitemid 44215349)
11. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
12. Chibnik LB, Massarotti EM, Costenbader KH. Identification and validation of lupus nephritis cases using administrative data. Lupus 2010;19:741-3.
13. Carls G, Li T, Panopalis P, Wang S, Mell AG, Gibson TB, et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med 2009;51:66-79.
14. Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large Medicaid population. Arthritis Rheum 2009;61:755-63.
15. Pelletier EM, Ogale S, Yu E, Brunetta P, Garg J. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database. Clin Ther 2009;31:2653-64.
16. Clinical Classifications Software (CCS) for ICD-9-CM, Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality, Rockville, MD, 2006-2009. [Internet. Accessed December 19, 2013.] Available from: www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp
17. American Academy of Pediatrics. Ages & Stages. [Internet. Accessed December 19, 2013.] Available from: www.healthychildren.org/English/ages-stages
18. Levy DM, Peschken CA, Tucker LB, Chedeville G, Huber AM, Pope JE, et al. Influence of ethnicity on childhood-onset systemic lupus erythematosus: results from a multiethnic multicenter Canadian cohort. Arthritis Care Res 2013;65:152-60.
19. Hiraki LT, Benseler SM, Tyrrell PN, Harvey E, Hebert D, Silverman ED. Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol 2009;36:2539-46.
20. Basu A, Manning WG, Mullahy J. Comparing alternative models: log vs Cox proportional hazard? Health Econ 2004;13:749-65. (Pubitemid 39136901)
21. Cassidy JT. Textbook of pediatric rheumatology, 6th ed. Philadelphia, PA: Saunders/Elsevier; 2011.
22. Alarcon GS, McGwin G Jr., Bastian HM, Roseman J, Lisse J, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum 2001;45:191-202. (Pubitemid 32954446)